Clinical Trial Update: Multi-Center Study Safety of Adipose Derived Mesenchymal Stem Cells for the Treatment of Multiple Sclerosis [Phase 1]

View source ↗

Summary

Phase 1 safety study evaluating autologous adipose-derived mesenchymal stem cells for multiple sclerosis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Autologous adipose-derived mesenchymal stem cells (adipose-derived mesenchymal stem cells)

Snippet

Sponsor: American CryoStem Corporation | Conditions: Multiple Sclerosis | Phase 1 | Status: TERMINATED